Evidence map›Paper›PMID 37834096›Full record

ArticleInternational journal of molecular sciences2023

Gibbs Energy and Gene Expression Combined as a New Technique for Selecting Drug Targets for Inhibiting Specific Protein-Protein Interactions.

Edward A Rietman, Hava T Siegelmann, Giannoula Lakka Klement, Jack A Tuszynski

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Edward A RietmanManning College of Information and Computer Science, University of Massachusetts, Amherst, MA 01003, USA.
Hava T SiegelmannManning College of Information and Computer Science, University of Massachusetts, Amherst, MA 01003, USA.ORCID 0000-0003-4938-8723
Giannoula Lakka KlementCSTS Healthcare 403 Melita St., Toronto, ON M6G 3X2, Canada.
Jack A TuszynskiDepartment of Mechanical and Aerospace Engineering, Politecnico di Torino, I-10129 Turin, Italy.ORCID 0000-0001-9976-0429

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

One of the most important aspects of successful cancer therapy is the identification of a target protein for inhibition interaction. Conventionally, this consists of screening a panel of genes to assess which is mutated and then developing a small molecule to inhibit the interaction of two proteins or to simply inhibit a specific protein from all interactions. In previous work, we have proposed computational methods that analyze protein-protein networks using both topological approaches and thermodynamic quantification provided by Gibbs free energy. In order to make these approaches both easier to implement and free of arbitrary topological filtration criteria, in the present paper, we propose a modification of the topological-thermodynamic analysis, which focuses on the selection of the most thermodynamically stable proteins and their subnetwork interaction partners with the highest expression levels. We illustrate the implementation of the new approach with two specific cases, glioblastoma (glioma brain tumors) and chronic lymphatic leukoma (CLL), based on the publicly available patient-derived datasets. We also discuss how this can be used in clinical practice in connection with the availability of approved and investigational drugs.

Indexed as

Brain NeoplasmsGliomaComputational BiologyGene ExpressionHumansProtein Interaction MapsProteinsThermodynamicsProteinschronic lymphocytic cancergliomaKEGGPPIprotein–protein interactionTCGA

Identifiers

PMID37834096
PMCPMC10572529

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.